OncoMatch/Clinical Trials/NCT07172204

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

Is NCT07172204 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Alternately treated with VA/low CHA regimen for intensive chemotherapy unfit.

Phase 2RecruitingFirst Affiliated Hospital of Zhejiang UniversityNCT07172204Data as of May 2026

Treatment: Alternately treated with VA/low CHA regimen — This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Biomarker criteria

Excluded: FLT3 itd mutation

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: aml-directed therapy

Exception: cytoreduction for hyperleukocytosis per institutional guidelines (hydroxyurea, leukapheresis); supportive growth factors

Lab requirements

Kidney function

severe renal insufficiency requiring dialysis

Liver function

child-pugh b or c cirrhosis, or hepatic impairment with total bilirubin >1.5×uln

Cardiac function

severe heart failure (congestive heart failure requiring treatment or myocardial infarction history with ejection fraction ≤50%)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify